Public - Physicians Database Login

1. Glémaud M, Illa L, Echenique M, Bustamente-Avellaneda V, Gazabon S, Villar-Loubet

O, Rodriguez A, Potter J, Messick B, Jayaweera DT , Boulanger C, Kolber MA. Abuse and Mental Health Concerns Among HIV-Infected Haitian Women Living in the United

States. J Assoc Nurses AIDS Care. 2013 Sep 24.

2. Tiozzo, E., Jayaweera, D ., Rodriguez, A., Konefal, J., Melillo A., Adwan, S., Chen, L.,

Parvus, C., Figueroa, M., Hodgson, N., Woolger, J., Kanka, R., Perry, A., and Lewis, J.

E. (2013). Short-term combined exercise training improves the health of human immunodeficiency virus (HIV)-infected patients. Journal of AIDS and HIV Research,

5(3), 80-89. Doi: 10.5897/JAHR12.076.

3. Jayaweera D , Dilanchian P. New therapeutic landscape of NNRTIs for treatment of HIV:

A look at recent data. Expert Opin Pharmacother. 2012 Dec;13(18):2601-12

4. Terrault N., Roland M., Schiano T., Dove L, Wong M., Poordad F., Ragni M., Barin B.,

Simon D., Olthoff K., Johnson L., Stosor, Dushyantha Jayaweera et al. Outcomes of liver transplantation in HCV-HIV coinfected recipients. Liver Transpl., 2012.18(6): p. 716-

726

5. Hodder S, Jayaweera D , Mrus J, Ryan R, Witek J; Grace Study Group. AIDS Res Hum

Retroviruses. 2012 Jun;28(6):544-51.Epub 2012 Apr 2.

6. Shin DH, Martinez SS, Parsons M, Jayaweera DT , Campa A, Baum MK. ionship of

Oxidative Stress with HIV Disease Progression in HIV/HCV Co-infected and HIV Monoinfected Adults in Miami. Int J Biosci Biochem Bioinforma. 2012; 2(3):217-223.

7. Nelson Mark, Amaya Gerardo, Clumeck Nathan, Arns da Cunha Clovis, Jayaweera,

Dushyantha et al Efficacy and safety of rilpivirine in treatmentnaïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the Phase III randomized, double-blind

ECHO and THRIVE trials. J of Antimicrobial Chemotherapy Volume 67, Number 8, 19

August 2012 , pp. 2020-2028(9)

8. Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-

Cremer N; AIDS Clinical Trials Group Study 175 Protocol Team. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. PLoS One. 2012;7(2):e31558. Epub 2012 Feb 21.

9. Jonathan Colasanti, Linda Nguyen, JoAnn Tjin Kon Kiem, Khaled Deeb, Dushyantha

Jayaweera; Disparities in HIV-treatment Responses between Haitians, African

Americans, and Hispanics Living in Miami-Dade County, Florida. Journal of Health Care for the Poor and Underserved 2012, 23: 179

–190

10. Vrouenraets S, Wit F, Fernandez Garcia E, Moyle G, Jackson A, Allavena C, Raffi F,

Jayaweera D, Mauss S, Katlama C, Fisher M, Slama L, Hardy W, Dejesus E, van

Eeden A, Reiss P; for the BASIC study group. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatmentnaïve

HIV-1-infected patients Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatmentnaïve HIV-1-infected patients HIV Medicine November 2011, 12 (10) , pp. 620-631

Dushyantha T. Jayaweera, M.D.

CV dated 27 th March 2015

Page 1 of 15

11. Baum, M, Sales S, Jayaweera, D . Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami.HIV Med. HIV Med. 2011 Feb;

12(2):78-86

12. Subramanium A., Sulkowski M., Barin B., Stablein D., Currey J.M., Nissen N., Dove L.,

Roland M., Florman S., Blumberg E., Stosor V., Jayaweera D.T

et al. MELD score is an

Important Predictor of Pre-Transplant Mortality in HIV-Infected Liver Transplant

Candidates. Gastroenterology 2010; 138; 159-164.

13. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R,

Tennenberg A, Mrus J, Squires K; GRACE (Gender, Race, And Clinical Experience)

Study Group. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Ann Intern Med. 2010 Sep 21;153(6):349-57

14. Wickramarathne T.L., Premaratne K., Kubat M,. Jayaweera D.T

. TKDE-2007-11-

0569.R2, "CoFiDS: A belief theoretic approach for Automated collaborative filtering;

IEEE Transactions on Knowledge and Data Engineering; 1/2010

15. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M,

Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13;23

(17):2289-300

16. Jayaweera D , DeJesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatmentnaïve HIV-1–infected patients over 96 weeks. .HIV

Clin Trials 2009;10(6):375 –384

17. Arasten K., Yani P, Pozniac A., Grinsztejn B, Jayaweera D . et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antiviral Therapy 2009; 14 (6):

18. Mills A.M, Nelson M, Jayaweera D , et al. Once-daily Darunavir/riotnavir vs

Lopinavir/ritonavir (LPV/r) in Treatmentnaïve, HIV-1-infected Patients 96 Week analysis.

AIDS. 2009 May 29. [Epub ahead of print]

19. Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, Bredeek

UF, Jayaweera D.T

, Guittari CJ, Larson P, Schutz M, Raffi F GEMINI. A noninferior study of Saquinavir/Ritonavir versus Lopinavir/Ritonavir as Initial Therapy in Adults. J

Acquir Immune Defic Syndr. J Acquir Immune Defic Syndr. 2009 Apr 1; 50 (4):367-74.

20. Cohen CJ, Berger DS, Blick G , Jayaweera D.T et al. Efficacy and safety of etravirine

(TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase

IIb trial.. AIDS. 2009 Jan 28;23(3):423-6

21. Drenna Waldrop-Valverde, Deborah L. Jones, Dushyantha Jayaweera , Peggy

Gonzalez, Javier Romero, & Raymond L. Ownby. Gender differences in medication



Page 2 of 15

management capacity in HIV infection: The role of health literacy and numeracy. AIDS

Behav. 2009 Feb;13(1):46-52

22. Dushyantha Jayaweera, Luis Espinoza and Jose Castro. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

Pharmacother. (2008) 9(17):1-12

23. Boyle B., Dushyantha Jayaweera , Mallory D Witt, MD et al. Simplification to a Once-

Daily Efavirenz-Based Highly Active Antiretroviral Therapy Regimen from a Twice-Daily or More Frequent Regimen Improves Adherence While Maintaining Viral Suppression.

HIV Clin Trials. 2008 May-Jun;9(3):164-76

24. M K Baum, C Rafie S, S Sales, S Lai, R Duan, D T Jayaweera , B Page and A Campa

Creactive protein: a poor marker of cardiovascular disease risk in HIVþ populations with high prevalence of elevated serum transaminases. International Journal of STD & AIDS

2008; 00: 1 –4

25. M.K. Baum, PhD, Dushyantha T. Jayaweera , MD,L Rui Duan, MD, Sabrina Sales, MS,

Shenghan Lai, MD, PhD, Carlin Rafie, MS, Arie Regev, MD, J. Bryan Page, PhD,

Ronald Berkman, PhD, Adriana Campa, PhD. Quality of Life, Symptomatology and

Healthcare Utilization in HIV/HCV Co-Infected Drug Users in Miami. Journal of Addictive

Diseases, Vol. 27(2) 2008

26. Adriana Campa, Dushyantha Jayaweera , Carlin Raffia Sabrina Sales et al. WHEN

“When Access to Antiretroviral Treatment for all” is not enough Journal of Public

Administration and Management, 2007;12(3):147-159

27. Ian Schreibman, Jeffrey J. Gaynor, Dushyantha Jayaweera , Nikolaos Pyrsopoulos,

Debbie Weppler, Andreas Tzakis, Eugene R. Schiff and Arie Regev, M.D. Outcomes

Following Orthotopic Liver Transplantation in Fifteen HIV-Infected Patients.

Transplantation 2007;84: 697 –705

28. The TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. Fast Track. AIDS 2007, 21:F1 –

F10

29. Bonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, David Cooper, Jean-

Christophe Goffard, Adriano Lazzarin, Andrej Wöhrmann, Christine Katlama, Timothy

Wilkin, Richard Haubrich, Calvin Cohen, Charles Farthing, Dushyantha Jayaweera ,

Martin Markowitz, Peter Ruane, Sabrina Spinosa-Guzman, Eric Lefebvre, on behalf of the POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials. www.thelancet.com Published online April 5, 2007

30. Joseph Gathe, David A. Cooper, Charles Farthing, Dushyantha Jayaweera , et al.

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced

Patients: 24-Week Analysis from the RESIST-1 Trial. Clin Infect Diseases 2006;43:1337-

1346



Page 3 of 15

31. Montaner JS. Schutz M. Schwartz R. Jayaweera DT et al Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviralnaive, HIV-infected patients . Medscape General Medicine. 2006 8(2):36

32. Neff G.W., Jayaweera D.T

., Sherman K. Drug induced Liver Injury in HIV Patients.

Gastroenterology and Hepatology 2006;2 (6) : 430-7

33. Ulrik Bak Dragsted, J Gerstoft, M Youle, Z Fox, M Losso, J Benetucci, D.T. Jayaweera ,

A Rieger, JN Bruun, A Castagna, B Gazzard, S Walmsley, A Hill, and JD Lundgren for the MaxCmin2 trial group. A randomized trial to evaluate the efficacy and safety of lopinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infected patients: The

MaxCmin2 Trial. Antiviral Therapy 2005; 10: 737-743

34. Jayaweera D.T

. Tipranavir: A ritonavir-boosted protease inhibitor: A viewpoint. Drugs.

2005; 65(12):1678-9

35. Rafael Campo, Rose Lalanne, Thomas Tanner, D. T. Jayaweera , Allan E. Rodriguez,

M. A. Kolber. Lopinarvir/Ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1 infected patients.

AIDS 2005, 19: 447-452

36. Jayaweera D. T ., Kolber M.A., Brill M, Tanner T., Campo R, Rodriguez A Chu M, Garg

V., Effectiveness and Tolerability of a Once Daily Amprenavir/Ritonavir Containing

HAART Regimen in Antiretroviral Naïve Patients at Risk for Non-Adherence: 48-Week

Results after 24 Weeks of Directly Observed Therapy. HIV Medicine 2004; 5:364-70

37. Patarca R, Isava A, Campo R, Rodriguez NJ, Nunez E, Alter M, Marchette M, Sanabia

MM, Mitchell C, Rivera D, Scott G, Jayaweera D. T ., Moreno J, Boulanger C, Kolber M,

Mask CW, Sierra EM, Vallejo R, Page JB, Klimas NG, Fletcher M.. Human

Immunodeficiency virus type 1, pharmacogenomics in clinical practice: relevance of

HIV-1 drug resistance testing (Part 1). J Environ Pathol Toxicol Oncol. 2003; 22(4):201-

25

38. Patarca R, Isava A, Campo R, Rodriguez NJ, Nunez E, Alter M, Marchette M, Sanabia

MM, Mitchell C, Rivera D, Scott G, Jayaweera D. T ., Moreno J, Boulanger C, Kolber M,

Mask CW, Sierra EM, Vallejo R, Page JB, Klimas NG, Fletcher M.. Human

Immunodeficiency virus type 1, pharmacogenomics in clinical practice: relevance of

HIV-1 drug resistance testing (Part 2). J Environ Pathol Toxicol Oncol. 2003; 22(4):235-

79

39. Campo RE, Rosa I, Lichtenberger PN, Suarez G, Rivera FA, Jayaweera D.T.

,

Rodriguez, AE, Wahlay NA, Kolber MA. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. AIDS Res Hum Retroviruses. 2003

Aug; 19(8):653-6

40. Campo RE, Lichtenberger PN, Rosa I, Suarez G, Rivera FA, Rodriguez AE, Jayaweera

D. T ., Wahlay NA, Kolber MA. Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates. J. Clin

Microbiol. 2003 July; 41(7):3376-8



Page 4 of 15

41. Maria Luisa Alcaide M.D., Dushyantha T. Jayaweera , M.D., Luis Espinoza M.D., M.

Kolber M.D., PhD. Wernicke’s Encephalopathy in AIDS: A Preventable and often not recognized cause of fatal neurological deficit. Int. J of STD and AIDS 2003; 14:D959.1-2

42. D.T. Jayaweera M.D., E. Scerpella M.D., M. Robinson*Pharm D et al. The Safety and

Efficacy of Indinavir and Ritonavir (400/400mg BID) in HIV-1 infected Individuals from an

Inner-City Minority Population. A Pilot Study. Int. J of STD and AIDS 2003; 14:841.1-5

43. Guy Neff, Eugene Schiff, John Fung, Margaret Ragni, Dushyantha Jayaweera .

Orthotopic liver transplantation in patients with human immunodeficiency virus and endstage liver disease. Liver Transplantation. March 2003; 9(3):239-47

44. Alcaide ML. MD, Kolber M; PhD, Jayaweera D. T . Would Switching the Protease

Inhibitors (PI) to Tenoforvir be an Option in Controlling Hypertriglyceridemia Secondary to PIs? A Case Report. Int. J of STD and AIDS 2002 Nov 13 (11):795-6

45. Chirgwin K, Hafner R; Leport C; Ramington J; Anderson J; Bosler EM; Roque C;

Jayaweera D. T ., et al. Randomized phase 11 trial of Atovoquane with pyrimethamine or sulfadiazine for the treatment of Toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study AIDS Clinical Trials Group.

Clin Infect Dis 2002 May 1;34(9) 1234-50

46. Neff G.W., Jayaweera D , Tzakis A. Liver Transplantation for HIV-infected patients with end stage liver disease. Current Opinion in Organ Transplantation 2002; 7(2):114-123

47. Patarca R, Isava A, Campo R, Rodriguez N., Jayaweera D. T . et al. Human

Immunodeficiency Virus Type 1 (HIV-1) Pharmacogenomics in Clinical Practice:

Relevance of HIV-1 Drug Resistance Testing. Critical Reviews in Oncogenesis 12

(1):47-106 (2001)

48. Kolber M.A., Gabr A.H., De La Rosa I., Glock, J.A., Jayaweera D.T., et al. Genotypic analysis of Plasma HIV-1 RNA after Influenza Vaccination of Patients with Previously

Undetectable Viral Loads. 2002, 16:1-6

49. Jacobson J.M., Hafner R., Jayaweera D.T.

Remington J. et al Dose escalation, Phase

1/11 study of azithromycin and pyremethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS 2001 Mar 30;15 (5) 583-9

50. Cheung T. W., Jayaweera D. T . Pearce D. et al. Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infection. Int. J of STD and AIDS 2000;11;640-647

51. Palmer C.J., Dubon J.M., Koenig E., Perez E., Ager A., Jayaweera D. T . et al; Field evaluation of the Determine rapid human immunodeficiency virus diagnostic test in

Honduras and the Dominican Republic. J Clin Microbiol 1999 Nov; 37 (11):3698-700

52. Verma Ashok, Schein Roland , Jayaweera D. T .et al. Fulminant axonal neuropathy with lactic acidosis and hyperglycemia associated with nucleoside analog therapy in an HIV patient. Case report. Neurology 1999; 53:1365-7



Page 5 of 15

53. Raez L., Cabral L., Cai J. P., Landy H., Sfakianakis G., Byrne G., Hurley J., Scerpella

E., Jayaweera D. T . Harrington W. Treatment of AIDs-Related Primary CNS lymphoma with Zidovudine, Ganciclovir, and Interleukin 2. AIDS Research and Human

Retroviruses 1999; 15:8:713-719

54. Jayaweera D. T ., Cassetti Lidia Isabel, Espinoza L. et al. Cytomegalovirus

Polyradiculomyelopathy in AIDS. Medicina (Buenos Aires) 1998;58:135-40

55. White D.J., Billingham C., Chapman S., Drake S., Jayaweera D.T., et al. Podophyllin

0.5% or 2% vs Podpohyllotoxin 0.5% for the self treatment of penile warts: a double blind randomized study. Genitourin Med 1997; 73:184-187

56. El-Dalil A.A., Jayaweera D.T.

, Walzman M., et al. Hepatitis B markers in heterosexual patients attending two genitourinary medicine clinics in West Midlands. Genitourin Med

1997; 73:127-130


. Minimizing the dosage-limiting toxicities of Foscarnet induction therapy. Drug experience. Drug Safety. 1997. (4) 258-266

58. Jayaweera D.T.

, Scerpella E.G., Rodriguez A.E., et al. Trombocitopenia asociada a infecciones con virus de immunodeficiencia humana tipo 1 (HIV-1): Tratamiento con danazol. Revista Medica Herediana 1996; 7 (4) 150-153


, White G., Moreno J. Pre-treatment with Hydration and Electrolytes

May Prevent Dose Limiting Toxicities During Foscarnet Induction Therapy. Genitourin

Med. 1995:6:223-226

60. White G.E., Ltjfrock V., Jayaweera D.T

. The over reporting of allergic reactions to medications in AIDS patients. Pharmacotherapy, 1996; 16:3:490

61. Huengsberg M., Jayaweera D.T.

, Wagstaffe S., et al. Toxoplasma Seroprevalence in

HIV-positive patient in West Midlands. Int J. of STD & AIDS 1995:6:223-226

62. Opaneye A.A., Jayaweera D.T.

, Walzman M., Wade A.H. PediculosisPubis: A surrogate Marker of Sexually Transmitted Diseases. J Roy Soc Health 1993:113:1:6-7

63. Barlow M., Jayaweera D.T.

, Wade A.A.et al. Laboratory techniques for the diagnosis of

Chlamydia Infections. Genitourin Med. 1991:67:6-522


, Ahmed I.H., Bignell C.J., Rogstad K.E. Genital warts and the need for screening. Genitourin Med. 1990; 66:4:305


, Vinasithambi S., Abeyawardane B.Y., Nimalasuriya A.,

Mihindukulasuriya J.C., Perera S.M., Machado V., Dharmadasa K. A case of vivax malaria presenting as an extra-pyramidal syndrome case report. Ceylon Med J. 1977

Mar; 22(1):64-5

Other works and publications (abstracts presented at National and International

Conferences):



Page 6 of 15

1. Khaled Deeb, Paula Dilanchia, Kanwal Razzaq, Carolyn Senk, Michael Kolber,

Dushyantha Jayaweera . HIV/HCV Co-Infection: Untreated Epidemic. CROI 2012.

Seattle, Washington March 4-8th Abstract # 751

2. Calvin Cohen, J-M Molina, Dushyantha Jayaweera et al. Relationship between

Combination of Baseline Viral Load and CD4 Cell Count, and Week 48 or 96 Responses to Rilpivirine or Efavirenz in Treatmentnaïve HIV-1+ Adults: Pooled Analysis from the

Phase 3 ECHO and THRIVE Trials. CROI 2012. Seattle, Washington March 4-8th

Abstract # 626

3. M Nelson, B Gazzard, S Walmsley, P Ruane, D Jayaweera et al Pooled Week 48 safety and efficacy results from ECHO and THRIVE Phase III trials comparing rilpivirine vs efavirenz in treatmentnaïve HIV-1-infected patients receiving FTC/TDF. 17th Annual

Conference of the British HIV Association 6-8 April 2011 Bournemouth, UK Poster# 183

4. Campa A, Jayaweera D , Lai S, et al. The effect of zinc supplementation on immune failure in HIV infected adults on stable antiretroviral therapy (ART). In Programs and abstracts of the 18th International AIDS Conference; July 18-23, 2010; Vienna, Austria.

Abstract MOPE0101.

5. Baum M. Marlink R, Jayaweera D , et al. Effect of antioxidant supplementation on immune reconstitution and mitochondrial damage. In Programs and abstracts of the 18th

International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract MOPE0102.

6. S Walmsley, M Nelson, P Ruane, D Jayaweera , et al. Pooled Week 48 safety and efficacy results from ECHO and THRIVE Phase III trials comparing rilpivirine vs efavirenz in treatmentnaïve HIV-1-infected patients receiving FTC/TDF. 20th Annual

Canadian Conference on HIV/AIDS Research, April 14-17, 2011, Toronto, Ontario

7. D Jayaweera , S Hodder, P Cahn, et al Safety, Efficacy and Subgroup Analyses of

Darunavir/ritonavir (DRV/r) Once-daily (qd) versus Twice-daily (bid), in Treatmentexperienced Patients with no DRV Resistance-Associated Mutations (RAMs). Abstract #

72. HIV DART 2010 December 7-10 Hilton, Los Cabos, Mexico

8. Colasanti J, Deeb K., and Jayaweera D.T

. Disparities in HIV-treatment Responses between Haitians, African Americans and Hispanics Living in the U.S.2010 National

Summit on HIV Diagnosis, Prevention and Access to Care The Forum for Collaborative

HIV Research - 2010 HIV Summit Posters. 12/10/2010 Washington DC. Abstract 99

9. Dushyantha Jayaweera, MD , Judith Aberg, MD, Turner Overton, MD, Samir Gupta,

METABOLIK (Metabolic Evaluation in Treatmentnaïves Assessing the impact of two

BOosted protease inhibitors on LIpids and other marKers): Week 48 Comparison of

Metabolic Parameters and Biomarkers in Subjects Receiving Darunavir/ritonavir or

Atazanavir/ritonavir, Abstract # 36. HIV DART 2010 December 7-10 Hilton, Los Cabos,

Mexico

10. Dushyantha Jayaweera, MD , Judith Aberg, MD, Turner Overton, MD, Samir Gupta,

METABOLIK: Week 12 Comparison of Metabolic Parameters and Biomarkers in ARV-



Page 7 of 15

naïve Subjects Receiving Darunavir/ritonavir or Atazanavir/ritonavir . 1 st International

Workshop on HIV & Aging, to be held October 4 –5

11. Disparities in HIV-treatment responses between Haitians, Colasanti Jonathan, Deab

Khaled, Jayaweera D.T

. African Americans and Hispanics living in the U.S. 2010

National Summit on HIV Diagnosis, Prevention, and Access to Care. Washington DC

November 18-19 2010

12. Dushyantha Jayaweera , Judith Aberg, Turner Overton, Samir Gupta, Bryan Baugh,

Robert Ryan, Guy De La Rosa. Metabolik Week 12 Comparison of Metabolic

Parameters and Biomarkers in ARVnaïve Subjects Receiving Darunavir/ritonavir or

Atazanavir/ritonavir. 1st International Workshop on HIV & Aging, 4 – 5 October 2010,

Baltimore, USA

13. Campa A Jayaweera D.T

., Lai S et al , The effect of zinc supplementation on immune failure in HIV infected adults on stable Antiretroviral Therapy (ART XVIII International

AIDS Meeting, Vienna, Austria July 18 th – 23 rd Poster # MOPE0101

14. Baum M, Marlink R., Jayaweera D . et al. Effect of antioxidant supplementation on immune reconstitution and mitochondrial damage XVIII International AIDS Meeting,

Vienna, Austria July 18 th –23 rd Poster # MOPE0102

15. Saskia Vrouenraets for the Study Team. A randomized open-label comparison of boosted ATV versus boosted SQV, both combined with TDF / FTC, on metabolic and renal outcomes in ART naïve HIV-1 infected patients. 12 Tth European AIDS Conference.

Cologne Germany 11-14 th November 2009 oral presentation

16. Hodder, S., Jayaweera D.T

., Mrus, J. et al. GRACE (Gender, Race And Clinical

Experience): Etravirine (ETR) Subgroup Analysis at Week 48. 49th Interscience

Conference on Antimicrobial Agents and Chemotherapy, (ICAAC) San Francisco, CA,

USA, September 12 –15, 2009

17. Campa A, Jayaweera DT, Sales S, Lai S. Baum MK. Zinc Supplementation Improves

Immune Response in HIV+ Adults Receiving Antiretroviral Treatment. 5 th IAS

Conference On HIV Pathogenesis Treatment and Prevention, Cape Town, South Africa,

July 19-23, 2009

18. Baum MK, Lai S, Jayaweera DT , Sales S, Campa A. Long-Term Zinc Supplementation

Delays Immunological Failure in HIV+ Drug Users in Miami. 5 th IAS Conference On HIV

Pathogenesis Treatment and Prevention, Cape Town, South Africa, July 19-23, 2009

19. N Terrault, B Barin, T Schiano, F Poordad, M Wong, M de Vera, D Simon, L Rosenthal,

D Jayaweera , et al Survival and Risk of Severe Hepatitis C Virus (HCV) Recurrence in

Liver Transplant (LT) Recipients Coinfected with Human Immunodeficiency Virus (HIV) and HCV. Accepted to AASLD Conference October 3-5 Boston 2009

20. D. Jayaweera , R. Ortiz, A. Mills, et al . ARTEMIS: Efficacy and Safety of

Darunavir/ritonavir (DRV/r) 800/100 mg Once-daily vs Lopinavir/ritonavir (LPV/r) in

Treatmentnaïve, HIV-1-infected Patients at 96 Weeks. DART conference, Puerto Rico

12-12-08. Oral presentation



Page 8 of 15

21. Vrouenraets SME, Fernado Garcia E, Jackson A., Raffie F., Jayaweeera D.T.

et al.

Saquinavir vs Atazanavir once daily, each boosted with100mg of ritonavir and combined with tenoforvir/emtricitabine result in comparable lipid changes after 24 weeks in treatment-naive HIV infected patients. Presented at the 10th International Workshop on

Advese Drug Reactions and Lipodystrophy in HIV November 6-8 2008 London JK.

Poster # 32

22. Mills A, Nelson M, Jayaweera D, ARTEMIS: Efficacy and Safety of Darunavir/ritonavir

(DRV/r) 800/100 mg Once-daily vs Lopinavir/ritonavir (LPV/r) in Treatmentnaïve, HIV-1infected Patients at 96 Weeks. 48th ICAAC /46th IDSA; October 25-28, 2008;

Washington, DC. Abstract H-896a

23. Dushyantha T. Jayaweera , and Gary E. Pakes, Improved Triglycerides After Reducing the Ritonavir (RTV) Boosting Dose from 200mg to 100mg Once Daily (QD) in HIV+

Patients Stabilized (Viral Load <50c/mL) on QD RTV-Boosted Fosamprenavir (FPV)

1400mg + Abacavir (ABC)600mg/Lamivudine (3TC)300mg. ACCP Annual Meeting

October 19 –22, 2008. Abstract # 14622

24. C. Rafie, A. Campa, S. Sales, D.T. Jayaweera , B.J. Page, S. Lai, M. Baum.

Heavy alcohol intake accelerates HIV disease progression independently of HAART and HIV viral load. XVII International AIDS Conference, Mexico City, Mexico, August 3-8, 2008

25. Campa, S. Sales, C. Rafie, K. Etengoff, K. Le, S. Lai, D.T. Jayaweera , F. Huffman, M.K.

Baum. Zinc supplementation reduces prevalence of diarrhea in HIV+ drug users. XVII

International AIDS Conference, Mexico City, Mexico, August 3-8, 2008

26. Pozniak A , Jayaweera D.

, Hoy J, De Meyer S, De Paepe E, Tomaka F. Efficacy of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the

POWER 1 and 2 trials. 11th European AIDS Clinical Society (EACS) Conference;

Madrid, Spain; 24 –27 October 2007. Abstract P7.2/07

27. Pierone G., Clotet B., Jayaweera D ., Neubacher D. Patients who responded to tipranavir (500/200mg) plus new enfuvirtide at week 16 of the RESIST studies maintained superior virological and immunological outcomes through week 96. 11th

European AIDS Clinical Society (EACS) Conference; Madrid, Spain; 24

–27 October

2007. Abstract P17.1/34

28. Baum MK. Jayaweera D , Huffman F, Sales S, Duan R, Rafie C, Regev A, Mendoza L,

Page JB, Campa A. HIV/HCV Co-Infection, Diarrhea and Healthcare Utilization in Drug

Users in Miami. Experimental Biology 2007 FASEB Conference, Washington DC, April

28-May 2, 2007

29. Sales S, Duan R, Jayaweera D , Bradwin G, Regev A, Rafie C, Page JB, Lai S,

Rodriguez P, Phillips JC, Baum MK, Campa A. Antioxidant Status in HIV Mono-infected and HIV/HCV Co-infected Drug Users in Miami. Experimental Biology 2007 FASEB

Conference, Washington DC, April 28-May 2, 2007

30. Duan R, Detrick B, Jayaweera D , Sales S, Rafie C, Lai S, Campa A, Baum MK.

Relationship of Adhesion Molecules with Markers of Liver Function and Serum Albumin



Page 9 of 15

in HIV/HCV Co-Infected Drug Users in Miami. Experimental Biology 2007 FASEB

Conference, Washington DC, April 28-May 2, 2007

31. Waldrop-Valverde D., Dushyantha Jayaweera , Allan Rodriguez, Mahendra Kumar &

Javier Romero. “Math and Memory Skills May Be Key for Accurate Understanding of

ART Instructions”. International Association of Physicians in AIDS Care, 2 nd International

Conference on HIV Treatment Adherence. March 28-30 in Jersey City, NJ Poster # - P-

321

32. Corrales-Medina V.F., Simkins J., Chirinos A., Symes S., Jayaweera D.T

. et Platelet

Microparticles, Platelets Activation and Platelet - Leukocyte Conjugates in HIV Infected

Patients with Optimal Response to Highly Active Antiretroviral Therapy (HAART)

American Society of Hematologist Meeting, Orlando FL December 9-12 th 2006. Abstract

# 1473

33. Simkins J., Corrales-Medina V.F., Chirinos A., Symes S., Jayaweera D.T.

et al.

Endothelial Microparticles (EMP) and their Interactions with Leucocytes in HIV Infected

Patients with Optimal Response to Highly Active Antiretroviral Therapy (HAART) .

American Society of Hematologist Meeting, Orlando FL December 9-12 th 2006. Abstract

# 1255

34. Jayaweera Dushyantha , Robinson M, Archer H, Riviera H., A Dedicated Minority Clinic for HIV Patients - A Strategy to Achieve HIV Treatment Success. 8 th HIV Congress on

Drug Therapy on HIV Infection 13-16 th November 2007 Glasgow, Scotland Abstract #

950513

35. Sension M., Jayaweera D.T

., Lacky P., et al. Impact of Race on efficacy and occurrence of Nervous system symptoms in HIV-Infected Patients following simplification from twice a day or more frequent HAART Regimens to a once a day

Efavirenz based Regimen. XVI International AIDS Conference Toronto, Canada. August

13-18, 2006. Abstract # THPE 0141

36. Duan R, Campa A, Zaveri M, Sales S, Xue L, Jayaweera DT , Page JB, Baum MK. C-

Reactive Protein (CRP) and Hepatitis C in HIV+ Drug Users in Miami. XVI International

AIDS Conference, Toronto, Canada, August 13-18, 2006. Abstract # WEPE 0061

37. Baum MK, Duan R, Xue L, Jayaweera DT , Campa A. Cytokine Profiles in HIV/Hepatitis

C Co-infected Drug Users in Miami. XVI International AIDS Conference, Toronto,

Canada, August 13-18, 2006. Abstract # WEPE 0042


Bellos N., Felizarta F. et al. A Once-Daily Efavirenz-Based Regimen for

Treatment-

Naïve HIV Patients: 96-Week Results from the DART II Trial: Infectious

Disease Society of America Meeting October 8 th 2005 Abstract # 800

39. Moreno J, Rivera H, Zambrano J, Jayaweera D.T

. Lack of Hepatotoxicity of Lopinavir

/ritonavir based regimens in patients attending an HIV/Hepatitis C co-infection clinic.

International AIDS Society Meeting Rio de Janeiro Brazil July 24-27th 2005 Abstract #

TuPe -1C22



Page 10 of 15

40. Shapiro J, Cahn P; Trottier B; Antunes F; Jayaweera D. T . et al. Effects of Baseline genotype on response to Tiprenavir/Ritonavir compared to standard of care comparator in treatment of experienced patients. Phase 3 RESIST STUDY in 2 trials. CROI 2005.

Boston Feb 22-25 th Abstract #104

41. Felizarta F., Becker S., Bellos N., Jayaweera D.T. et al.

Adherence and efficacy with a once-daily Efavirenz-based regimen: 48 week results from the daily antiretroviral therapy II (DART II) study. International AIDS Society Meeting Bangkok Thailand July

12 th 2004 Abstract # WePeB5842

42. K. Baum, L. Karas, S. Lai, W. Zaidi, P. Johnson, F. Huffman, L. Xue, J.C. Phillips, V.

Daniel, D. Jayaweera , et al. Metabolic syndrome in an HIV+ drug using population in

Miami. International AIDS Society Meeting Bangkok Thailand July 12 th 2004 Abstract #

WePeB5872


, Becker S., Bellos N., et al. A once daily efavirenz-based regimen for treamentnaïve HIV patients: 48 week efficacy and safety results from the DART II trial.

International AIDS Society Meeting Bangkok Thailand July 12 th 2004 Abstract #

TuPeB4510

44. Chin-Beckford N., Kaul S., Jayaweera D.T

. Co-morbidities drive nephrotoxicity associated with tenofovir fumarte. A case series. International AIDS Society Meeting

Bangkok Thailand July 12 th 2004 Abstract # WePeB 5970


, Lolayekar S., Campo R., et al. Direct observed therapy (DOT) for 6 months and weekly contact for 6 months to a resource poor, inner-city minority population with inadequate HIV knowledge and advanced AIDS, has good results at 96 weeks. International AIDS Society Meeting Bangkok Thailand July 12 th 2004 Abstract #

ThPeB 7217

46. Jayaweera D.

, Tanner T, Brill M., Campo R., Rodriguez A., Kolber M., Gharakhanian S.,

Garg V. Evaluation De La Methode, Traitment Directment Observe (TDO) AU Cours D

L’Infection VIH: Resultats A 48 Semaines es Apres 24 Semaines de TDO. French

Infectious disease conference in Lille May 2003, Poster #A29

47. Jayaweera D. T ., Becker S., Felizarta F., et al. DART 2 Once daily HIV therapy for antiretroviral naïve patients using Stavudine XR, Lamivudine and Efavirenz. 9 th

European AIDS Conference (EACS) in Warsaw, Poland, October 28, 2003

48. Ulrik Bak Dragsted, Gerstoff J., Youle M., Duran A., Jayaweera D. T . et al. The Week

24 Interim Analysis of a Randomized, Open-label, Phase IV, Multi-center Trial to

Evaluate Safety and Efficacy of Lopinavir/Ritonavir (400/100mg bid) Versus

Saquinavir/Ritonavir (1000/100 mg bid): The MaxCmin2 Trial Presented at International

AIDS Conference in Paris July 9, 2003

49. Boulanger C, Ha B, Desrosiers M, Simon V., Jayaweera D . Rifabutin when given twice a week with Ritonavir Boosted Amprenavir in a Once Daily HAART Regimen may Result in Sub-therapeutic levels of rifabutin, despite Directly Observed Treatment. International

PK meeting in Cans Abstract # 299an, France March 27-28.2003



Page 11 of 15

50. Yeni P., MacGregor T., Gathe J., Arasteh K., Jayaweera D.

et al. Correlation of Viral

Load Reduction and Plasma Levels iin Multiple Protease Inhibitor (PI) Experienced

Patients Taking Tipranavir/Ritonavir (TPV/r) in a Phase IIB. 10 th Conference on

Retroviruses and Opportunistic Infections. Boston 10-14 th Feb 2003 #596

51. Cooper D., Hall D., Jayaweera D.T., et al Baseline Phenotypic Susceptibility to

Tipranavir/Ritonavir (TPV/r) is Retained in Isolates from Patients with Multiple Protease

Inhibitor (PI) Experience (BI 1182.52). 10 th Conference on Retroviruses and

Opportunistic Infections. Boston 10-14 th Feb 2003 #528

52. Ulrik Bak Dragsted, Gerstoff J, Youle M, Duran A, Jayaweera D. T.

et al. The Week 24

Interim Analysis of a Randomized, Open-label, Phase IV, Multi-center Trial to Evaluate

Safety and Efficacy of Lopinavir/Ritonavir (400/100 mg bid) Versus Saquinavir/Ritonavir

(1000/100 mg bid): The Max Cmin2 Trial Presented at International Aids Conference in

Glasgow 11/20/02 Abstract # PL 14.5

53. Jayaweera D ., Slater L; Haas D., et al Susceptibility Profile of Tiprenavir at Baseline and

Virologic response of a cohort of patients with single protease inhibitor failure. 2 nd

International Workshop of Treatment Experienced Patients 9-26-02 San Diego # P5

54. Neff G.T., Jayaweera D.T.

, Hung O., et al. Solid Organ Transplantation in Patients with

Human Immunodeficiency Syndrome: A Successful Case Series long term follow up.

ICCAC September 28, 2002. Poster 1205

55. O’Brian W., Rojo D., Accosta E., Felizarta F., Pearce D., Jayaweera D . et al. Switch of

Saquinavir 400 mg/Ritonavir 400mg to Saquinavir 1000mg/Ritonavir 100mg bid, 4 drug

ARV therapy in patients with viral loads <200 copies/ml.3

rd International Workshop on

Clinical Pharmacology and HIV Therapy. XIII International AIDS Conference, Barcelona,

Spain July 7-12, 2002


, Tanner T., Novak A., Brill M., Pottage J., Campo R., Rodriguez A.,

Antiviral potency and tolerability of convenient once a day direct observed therapy with

Ampre navir containing HAART regimen in an antiretroviral naïve, inner-city minority patients with poor HIV knowledge and very advance AIDS. XIII International AIDS

Conference, Barcelona, Spain July 7-12, 2002. Abstract #TuPeB 5793

57. Jayaweera D . T., Tanner T., Novak A., Brill M., Pottage J., Campo R., Rodriguez A.,

Kolber M. Direct Observed Therapy (DOT) in HIV is it a Feasible in Clinical Practice?

Problems Associated with DOT an Amprenavir containing HAART regimen in an antiretroviral naïve, inner-city minority patients with poor HIV knowledge and very advanced AIDS. XIII International AIDS Conference, Barcelona, Spain July 7-12, 2002.

Abstract # TuPeE5128

58. Garg V., Brill ,., Beeler L., Pottage J., Rodriguez A., Campo R., Tanner T., Jayaweera

D.T

. Effectiv e Plasma Levels of Amprenavir in Highly Challenging, Naïve HIV Patients

Following a Once Daily HAART Regimen. XIII International AIDS Conference,

Barcelona, Spain July 7-12, 2002. Abstract # TuPeB 4503

59. O’Brian W., Rojo D., Accosta E., Felizarta F., Pearce D., Jayaweera D et al. Switch of

Saquinavir 400mg/Ritonavir 400mg to Saquinavir 1000mg/Ritonavir 100 mg bid, 4-drug



Page 12 of 15

ARV therapy in patients with viral loads < 200 copies/ml. 3rd International Workshop on

Clinical Pharmacology and HIV Therapy. Washington DC, April 13, 2002. Abstract #2.1

60. Garg V., Brill A., Rodriguez A., Tanner T., Beeler L., Pottage J., Jayaweera D. T .

Clinical Pharmacology of Amprenavir in Highly Challenging naïve patients following once a day HAART regimen under Directly Observed Therapy. 3 rd International Workshop on

Clinical Pharmacology and HIV Therapy. Washington DC, April 13, 2002. Abstract #2.5

61. Neff G.T., Jayaweera D.T.

, Hung O., et al. Solid Organ Transplantation in Patients with

Human Immunodeficiency Syndrome: A Successful Case Series. ICCAC 12/21/01

Poster 1-205

62. J.S.G. Montaner, R Schwartz, D. Jayaweera , C, Barylski, et al Focus on African

Americans Receiving QD Saquinavir Soft Gel Capsules for PK, PD, and Safety. ICCAC

12/21/01 Poster 1-203

63. Campo R., Suarez G., Rosa I., Rivera F., Jayaweera D. T ., et al. Relationship between

Prior Antiretroviral Therapy (ART) and Genotypic Testing among a large Cohort of HIV-1 clinical isolates. ICCAC 12/21/01 Poster 713

64. Schwartz R., Jayaweera D.T

., De Capraris P. et al Pharmacokinetic Evaluation of HIV+

African American, Caucasians On Once Daily (QD) Saquinavir Soft Gel Capsules (SQV) and Mini Dose Ritonavir (rtv). Schwartz R; Jayaweera D. T.; De Capraris P. et al Poster

#313 Pharmacokinetic and Therapeutic drug Monitoring Conference, Amsterdam 4/3/01

65. Jayaweera D. T., Murphy R., Green S. et al. A Unique Strategy for Salvage Therapy in

HIV. Updated safety data: Safety of EF 10, Macrophage Regulator, in Patients with <50

CD4+ T cells/mm3, safety data. DART conference in Puerto Rico 12/20/2000. Abstract

66. Scerpella E., Jayaweera D. T ., Lalanne R., Asthana D., Kolber M. Antiretroviral potency and tolerability of a convenient 2-drug regimen, ritonavir and indinavir in antiretroviral naïve, inner-city minority patients with advanced AIDS and/or high viral loads. XIII

International AIDS Conference, Durban, South Africa July 9-11, 2000 Abstract WePeB

4232

67. Jayaweera D. T ., Scerpella E., Lalanne R., Asthana D., Kolber M. Antiretroviral potency and tolerability of a convenient 2-drug regimen, ritonavir in antiretroviral naïve, inner-city minority patients with advanced AIDS and/or high viral loads. XIII International

AIDS Conference, Durban, South Africa July 9-11, 2000 Abstract TuOrB 299


; Murphy R; Green S. et al. A Unique Strategy for Salvage Therapy in

HIV: Updated safety data. Safety of EF 10, Macrophage Regulator, in Patients with <

50 CD4+ T cells/mm3, safety data. Vaccine and Immune Therapy Conference in Palm

Beach 6/15/2000. Abstract.# 201

69. Scerpella E., Jayaweera D. T .,Rodriguez A., Moreno J. et al. Predictors of Response to ritonavir and saquinavir salvage therapy in antiretroviral experienced patients; 3 year follow up. Salvage Therapy Conference in Chicago 4/15/2000. Abstract.# 57



Page 13 of 15

70. Jayaweera D. T ; Murphy R., Green S., et al. A Unique Strategy for Salvage Therapy in

HIV: Safety of EF 10, Macrophage Regulator, in Patients with < 50 CD4+ T cells/mm3.

Salvage Therapy Conference in Chicago 4/15/2000. Abstract # 36

71. White G.E., Jayaweera D.T

., Karen Hobby-Henderson et al. An evaluation

Amphotericin B induced nephrotoxicity in adult AIDS patients being treated for systemic fungal infections. American College of Clinical Pharmacy 4/6/98 Palm Springs

California. Abstract # 53

72. Scerpella E., Moreno J., Dashefsky M., Jayaweera D. T . et al. Ritonavir + Saquinavir

(RIT +SAQ) salvage therapy in antiretroviral-experienced patients. 12 th World AIDS conference Geneva 6/28/98. Abstract # 12310

73. Raez Luis, Lee R; Cabral L., Cai G., Sfakianakis E., Scerpella E., Jayaweera D. T.

et al.

Antiviral induce apoptosis and tumor regression in AIDS-Related CNS Lymphoma 12 th

World AIDS conference Geneva 6/28/98. Abstract # 2497

74. Kozal M., Leahy N., Agar A., Jayaweera D. T.

Prevalence of HIV-1 drug Resistance mutations in an tiretroviral naïve patients at an inner city University of Miami HIV clinic in

Miami. Abstract 115.2

nd International Work Shop on HIV Drug Resistance and

Treatment Strategies. July 24, 1998.Lake Maggiore, Italy

75. Raez Luis, Hurley J; Jayaweera D. T . et al. Treatment of AIDS related primary CNS lymphoma with AZT, ganciclovir and Interleukin-2. American Society of Hematology

12/5/97

76. Benson P; Nahass R; Deresinki S; Grossman R; Scolara M; Cheung T; Fiala M; Karedes

J; Pearce D; Cone L; Jayaweera D. T . et al. Safety of Oral therapy vs Intravenous

Hydration during Induction Therapy with Intravenous Foscavir. 4 th Conference on

Retroviruses and Opportunistic Infections, Jan 22-26, 1997. Abstract # 299

77. Sylvester S; Caliendo A; Septkowitz K, Fischl M, Jayaweera D , Simon G, Lalezari J,

Mitsuyas R; D’ Aquila R. HIV-1 Resistance Mutations and Plasma RNA Levels during

ZDV and ddC Combination Therapy. New York Hospital, University of Miami, George

Washington University, University of San Francisco CA, University of Los Angeles CA,

Harvard Medical School and Massachusetts General Hospital. 3 rd Conference on

Retroviruses and Opportunistic Infections January 28-Feb 1, 1996. Abstract # 339

78. White G, Jayaweera D.T

., Clark J. Implementation of Clinical Pharmacy Services in

Primary Care Ambulatory AIDS Clinic. 2 nd International Conference on Home and

Community Care for Persons Living with HIV/AIDS. May 24-27, 1995

79. Laird K., Jayaweera D.T

. Microsporidial Keratoconjuctivitis in Four Patients with AIDS.

IDSA Meeting 9/16/95-9/18/95. Abst #: 285

80. Echavarria F., Jayaweera D.T., Scerpella E. et al. Danazol therapy in

Thrombocytopenia associated with human immunodeficiency virus type 1 (HIV-1) infection. ACP meeting, Orlando, 10/18/95



Page 14 of 15

81. Echavarria F, Jayaweera D.T, Scerpella E. et al. Tuberculosis liver abscess in acquired immunodeficiency syndrome: Report of one case and review of the literature. ACP meeting, Orlando, 10/18/95

82. Dalil A, Jayaweera D.T.

, Wade A, Shahmanesh M. A prospective controlled survey of hepatitis B virus (HBV) seroprevalence in patients attending two genitourinary medicine clinics in the West Midlands. MSSVD spring meeting 6-9 May 1993, Zurich, Switzerland

83. Opaneye AA, Jayaweera D.T.

, Waltzman M, Wade AA. Associated sexually transmitted disease among asymptomatic patients requesting HIV serology in Coventry. MSSVD conference, Dublin, Ireland. 6/19/92

84. Jones S, Jayaweera D.T.

, Opaneye AA, Waltzman M, Wade A. Clinical audit in gonorrhea: A slide culture correlation. MSSVD conference, Dublin Ireland. 6/19/92


, Wagstaff S, Opaneye A, Wade A, Shahmanesh M. Toxoplasma seroprevalence in HIV patients in West Midlands. MSSVD conference, Dublin, Ireland

6/19/92


, Opaneye AA, DeSilva Y, Waltzman M, Wade A. Primary case pattern of sexually transmitted diseases including HIV in Coventry. MSSVD Conference, Dublin,

Ireland. 6/19/92

87. Jayaweera D. T . Is bacterial vaginosis more common in female contacts of men with

Non-Gonococcal urethritis? MSSVD Conference at Heidelberg, Germany, 1991

88. Jayaweera D. T . Genital warts and screening for sexually transmitted diseases.

(Presented, Annual Sessions of the Northern Genitourinary Physicians Colposcopy

Group, Manchester, U.K; 1990)



Page 15 of 15

Public - Physicians Database Login

Related documents

Products

Support

Public - Physicians Database Login

Related documents

Add this document to collection(s)

Add this document to saved

Suggest us how to improve StudyLib